Depleting the biomarker of one of the most lethal form of brain tumours in adults could prevent its progression and relapse.
Researchers found the biomarker miR-138 is more prominent in cancer stem cells than in normal neural stem cells. However when miR-138 is depleted (because of a drug called anti-miR-138), the cancer cells are destroyed entirely.
Identifying and targeting the regulator, which is responsible for the advancement and relapse of the caner, could effectively prevent it from recurring.
Researchers say it could also create potential for the development of an alternative treatment for aggressive forms of brain cancer.